bioRxivPathology
VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis
F. Rizvi, Y.-R. Lee, R. Diaz-Aragon, J. So, R. M. Florentino, A. R. Smith, E. Everton, A. Ostrowska, K. Jung, Y. Tam, H. Muramatsu, N. Pardi, D. Weissman, A. Soto-Gutierrez, D. Shin, V. Gouon-Evans
Abstract
The liver is known for its remarkable regenerative ability through proliferation of hepatocytes. Yet, during chronic injury or severe hepatocyte death, proliferation of hepatocytes is exhausted. To overcome this hurdle, we propose vascular-endothelial-growth-factor A (VEGFA) as a therapeutic means to accelerate biliary epithelial cell (BEC)-to-hepatocyte conversion. Investigation in zebrafish establishes that blocking VEGF receptors abrogates BEC-driven liver repair, while VEGFA overexpression promotes it. Delivery of VEGFA via non-integrative and safe nucleoside-modified mRNA encapsulated into lipid-nanoparticles (mRNA-LNP) in acutely or chronically injured mouse livers induces robust BEC-to-hepatocyte conversion and reversion of steatosis and fibrosis. In human and murine diseased livers, we further identified VEGFA-receptor KDR-expressing BECs associated with KDR-expressing cell-derived hepatocytes. This defines KDR-expressing cells, most likely being BECs, as facultative progenitors. This study reveals novel therapeutic benefits of VEGFA delivered via nucleoside-modified mRNA-LNP, whose safety is widely validated with COVID-19 vaccines, for harnessing BEC-driven repair to potentially treat liver diseases. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=156 SRC="FIGDIR/small/537186v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@8ce1bdorg.highwire.dtl.DTLVardef@1385103org.highwire.dtl.DTLVardef@4ec496org.highwire.dtl.DTLVardef@14c9295_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIComplementary mouse and zebrafish models of liver injury demonstrate the therapeutic impact of VEGFA-KDR axis activation to harness BEC-driven liver regeneration. C_LIO_LIVEGFA mRNA LNPs restore two key features of the chronic liver disease in humans such as steatosis and fibrosis. C_LIO_LIIdentification in human cirrhotic ESLD livers of KDR-expressing BECs adjacent to clusters of KDR+ hepatocytes suggesting their BEC origin. C_LIO_LIKDR-expressing BECs may represent facultative adult progenitor cells, a unique BEC population that has yet been uncovered. C_LI
- organism: mouse
- organism: zebrafish
- organism: human
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: development & morphogenesis
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases
A. R. Smith, F. Rizvi, … V. Gouon-Evans·bioRxiv·Jan 11, 2024
- Enhanced liver regeneration via targeted mRNA delivery for partial in vivo reprogramming
Beom‐Ki Jo, Young Seok Song, … Hyuk‐Jin Cha·Cell Reports MedicinePeer-reviewed·Oct 1, 2026
- Hepatic lipid overload potentiates biliary epithelial cell activation via E2Fs
E. Yildiz, G. El Alam, … K. Schoonjans·eLifePeer-reviewed·Mar 6, 2023
- Immunomagneto-activated hepatocyte-specific tissue vesicle profiling reveals message diversification from regenerating liver
- The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs
Wenjing Zhou, Tanja Diemer, … Napoleone Ferrara·bioRxiv·Feb 25, 2026
- In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis
Chittampalli N. Yashaswini, Bruno Cogliati, … Scott L. Friedman·bioRxiv·Feb 25, 2025